Eiger BioPharmaceuticals Investor Relations Material

Eiger BioPharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases. The company’s therapeutic areas include infectious diseases, metabolic disorders, and genetic conditions. Eiger’s pipeline targets diseases with high unmet medical needs, and it works to bring new treatment options to patients who have limited alternatives. Its approach involves repurposing existing drugs and developing novel compounds to advance its treatment options through clinical trials and regulatory approvals. The company is headquartered in Palo Alto, California, and its shares are listed on the NASDAQ.